Terapêutica biológica na rinossinusite crónica com polipose nasal: um estudo retrospetivo
DOI:
https://doi.org/10.34631/sporl.3129Palavras-chave:
Rinossinusite crónica, Anticorpos monoclonais, Dupilumab, Mepolizumab, Sniffin’ sticksResumo
Objetivos: Descrever a casuística de doentes com rinossinusite crónica com polipose nasal (RSCcPN) sob terapêutica biológica num hospital terciário.
Desenho do Estudo: Estudo retrospetivo observacional.
Material e Métodos: Grupo de doentes com RSCcPN sob terapêutica biológica entre abril/2023 e dezembro/2024. Avaliação clínica nas semanas 0, 4 e 16. O sucesso terapêutico foi determinado segundo os critérios EPOS/EUFOREA 2023, através do NPS, NOSE, SNOT-22, VAS de olfato e obstrução nasal, e Sniffin’ Sticks. A análise estatística foi realizada através dos testes de Friedman e Wilcoxon (p<0.05).
Resultados: Foram incluídos 23 doentes sob terapêutica com Dupilumab ou Mepolizumab. Verificou-se redução do NPS, SNOT-22, VAS de olfato e VAS de obstrução nasal (p<0.0001) e um aumento do score de Sniffin’ Sticks (p<0.001) entre a semana 0 e 16.
Conclusões: A terapêutica biológica demonstrou eficácia sintomática e na melhoria da qualidade de vida em doentes com RSCcPN que não respondem à terapêutica convencional.
Downloads
Referências
Fokkens W, Van Der Lans R, Reitsma S. Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis. Expert Opin Biol Ther. 2021 May;21(5):575-585. doi: 10.1080/14712598.2021.1901881.
Fokkens WJ, Viskens AS, Backer V, Conti D, De Corso E, Gevaert P. et al. EPOS/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023. Rhinology. 2023 Jun 1;61(3):194-202. doi: 10.4193/Rhin22.489.
Bachert C, Marple B, Schlosser RJ, Hopkins C, Schleimer RP, Lambrecht BN. et al. Adult chronic rhinosinusitis. Nat Rev Dis Primers. 2020 Oct 29;6(1):86. doi: 10.1038/s41572-020-00218-1.
Bachert C, Hicks A, Gane S, Peters AT, Gevaert P, Nash S. et al. The interleukin-4/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polyps. Front Immunol. 2024 Apr 16:15:1356298. doi: 10.3389/fimmu.2024.1356298.
Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S. et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020 Feb 20;58(Suppl S29):1-464. doi: 10.4193/Rhin20.600.
Infarmed. Autoridade Nacional do Medicamento e Produtos de Saúde I.P. Autorização de introdução no mercado [Internet]. Lisboa: Infarmed; [cited 2025 Apr 15]. Available from: https://www.infarmed.pt/web/infarmed/entidades/medicamentos-uso-humano/autorizacao-de-introducao-no-mercado
Sanofi. A randomized, 24-week treatment, double-blind, placebo-controlled efficacy and safety study of dupilumab 300 mg every other week, in patients with bilateral nasal polyposis on a background therapy with intranasal corticosteroids [Internet]. clinicaltrials.gov; 2019 Jul. Report No.: NCT02912468. [cited 2025 Apr 15]. Available from: https://fdaaa.trialstracker.net/trial/NCT02912468/
Sanofi. A randomized, double-blind, 52-week, placebo controlled efficacy and safety study of dupilumab, in patients with bilateral nasal polyposis on a background therapy with intranasal corticosteroids [Internet]. clinicaltrials.gov; 2019 Oct. Report No.: NCT02898454. [cited 2025 Apr 15]. Available from: https://fdaaa.trialstracker.net/trial/NCT02898454/
Hoffmann-La Roche. A phase III, randomized, multicenter, double-blind, placebo-controlled clinical trial of omalizumab in patients with chronic rhinosinusitis with nasal polyps [Internet]. clinicaltrials.gov; 2020 Mar. Report No.: NCT03280537. [cited 2025 Apr 15]. Available from: https://fdaaa.trialstracker.net/trial/NCT03280537/
Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE. et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 Oct;9(10):1141-1153. doi: 10.1016/S2213-2600(21)00097-7.
Silver J, Packnett E, Park J, Deb A. Biologic use and treatment patterns in patients with chronic rhinosinusitis with nasal polyps: a US real-world study. Allergy Asthma Clin Immunol. 2023 Dec 8;19(1):104. doi: 10.1186/s13223-023-00855-7.
Soler ZM, Patel ZM, Mullol J, Mattos J, Nash S, Xia C. et al. Association between smell loss, disease burden, and dupilumab efficacy in chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2025 Jan;39(1):6-12. doi: 10.1177/19458924241274501.
Galletti C, Ragusa M, Sireci F, Ciodaro F, Barbieri MA, Giunta G. et al. Dupilumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience. Am J Otolaryngol. 2024 Jan-Feb;45(1):104106. doi: 10.1016/j.amjoto.2023.104106.
Book R, Eligal S, Tal Y, Eliashar R. Biological treatment for uncontrolled chronic rhinosinusitis with nasal polyps: preliminary real-world results from a Tertiary Medical Center. J Clin Med. 2023 May 25;12(11):3671. doi: 10.3390/jcm12113671.
Downloads
Publicado
Como Citar
Edição
Secção
Licença
Direitos de Autor (c) 2025 Beatriz Nicolau, Cláudia Geraldes, André Alves Pereira, Tiago Infante Velada, Jorge Mexia, Herédio de Sousa
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição-CompartilhaIgual 4.0.
